The high-dose rosuvastatin once weekly study (The HD-ROWS)
Journal of Clinical Lipidology, 07/27/2012
Clinical Article
Backes JM et al. – Rosuvastatin 80 mg once weekly produced comparable lipid changes to atorvastatin 10 mg daily when measured at specific points after the last dose. Our findings support previous data demonstrating a significant reduction in LDL–C with once weekly statin dosing.
Methods- This was a randomized, double–blind, parallel group, 8–week pilot study.
- Eligible subjects, 18 to 65 years of age, had documented dyslipidemia with LDL cholesterol >100 mg/dL and triglycerides <200 mg/dL.
- Participants were randomized to receive either rosuvastatin 80 mg once weekly (n = 10) or atorvastatin 10 mg daily (n = 10), for 8 weeks.
- Lipid panels and hsCRP were measured at baseline and 1–4 and 5–8 days after the last dose.
- Participants in each arm experienced significant and comparable reductions from baseline in total cholesterol, total cholesterol/high–density lipoprotein cholesterol ratio, non–high–density lipoprotein cholesterol, and overall LDL cholesterol (–29%).
- Changes in high–density lipoprotein cholesterol, triglycerides, and hsCRP were nonsignificant and similar between groups.
- Each regimen was well tolerated, with no major adverse events reported.



